End points for new agents in induction chemotherapy for locally advanced head and neck cancers

被引:78
作者
Monnerat, C
Faivre, S
Temam, S
Bourhis, J
Raymond, E
机构
[1] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Dept Head & Neck Surg, F-94805 Villejuif, France
[3] Inst Gustave Roussy, Dept Radiotherapy, F-94805 Villejuif, France
关键词
head and neck cancer; neoadjuvant chemotherapy; new drugs; new methodology; taxanes;
D O I
10.1093/annonc/mdf172
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
More than 60% of patients diagnosed with squamous cell carcinoma of the head and neck present at a locally advanced stage. Although multimodality therapy has improved locoregional control, the 5-year survival rate of this population rarely exceeds 30%. In this review, we analyzed the impact of chemotherapy in the management of locally advanced head and neck cancer and we underline the potential benefit of induction chemotherapy. The Meta-Analysis of Chemotherapy in Head and Neck Cancer collaborative group has suggested a survival advantage of 5% at 5 years for platin-5-fluorouracil induction chemotherapy. We have analyzed cofactors that may affect the survival of head and neck patient,,, and propose new end points for assessment of the efficacy of induction chemotherapy. The detrimental effect of second primary tumors on long-term results is stressed and we have suggested the use of overall 2-year survival as a surrogate end point for induction chemotherapy efficacy. Finally, we have examined the impact of new cytotoxic agents and present the promising results of new taxane-based combinations.
引用
收藏
页码:995 / 1006
页数:12
相关论文
共 109 条
[1]   Induction chemotherapy in head and neck cancer [J].
Adelstein, DJ .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (04) :689-+
[2]  
ADELSTEIN DJ, 2000, P AN M AM SOC CLIN, V19, pA411
[3]   Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099 [J].
Al-Sarraf, M ;
LeBlanc, M ;
Giri, PGS ;
Fu, KK ;
Cooper, J ;
Vuong, T ;
Forastiere, AA ;
Adams, G ;
Sakr, WA ;
Schuller, DE ;
Ensley, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1310-1317
[4]  
[Anonymous], 1987, CANCER-AM CANCER SOC, V60, P301
[5]  
[Anonymous], 1986, EUR J SURG ONCOL, V12, P289
[6]   POSITRON EMISSION TOMOGRAPHY IN THE DETECTION OF RESIDUAL LARYNGEAL CARCINOMA [J].
AUSTIN, JR ;
WONG, FC ;
KIM, EE .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1995, 113 (04) :404-407
[7]  
Biakhov M, 2000, ANN ONCOL, V11, P92
[8]  
Black, 1997, EUR J CANCER, V33, P2440
[9]   Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990 [J].
Black, RJ ;
Bray, F ;
Ferlay, J ;
Parkin, DM .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (07) :1075-1107
[10]   Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer [J].
Brizel, DM ;
Albers, ME ;
Fisher, SR ;
Scher, RL ;
Richtsmeier, WJ ;
Hars, V ;
George, SL ;
Huang, AT ;
Prosnitz, LR .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (25) :1798-1804